

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5504059

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
NOVARTIS AG	11/26/2018
VIVACTA LIMITED	11/26/2018
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	PSYROS DIAGNOSTICS LIMITED
<b>Street Address:</b>	41B BEACH ROAD
<b>City:</b>	LITTLEHAMPTON, WEST SUSSEX, ENGLAND
<b>State/Country:</b>	UNITED KINGDOM
<b>Postal Code:</b>	BN17 5JA
<b>PROPERTY NUMBERS Total: 9</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	15575670
Patent Number:	8758686
Patent Number:	8524504
Patent Number:	9638691
Patent Number:	9057723
Patent Number:	8512966
Patent Number:	8845965
Patent Number:	9068930
Patent Number:	10078079
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(312)876-2020
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(312) 876-1800
<b>Email:</b>	adiaz@woodphillips.com
<b>Correspondent Name:</b>	WOOD PHILLIPS KATZ CLARK & MORTIMER
<b>Address Line 1:</b>	500 W. MADISON STREET
<b>Address Line 2:</b>	SUITE 1130
<b>Address Line 4:</b>	CHICAGO, ILLINOIS 60661
<b>ATTORNEY DOCKET NUMBER:</b>	ELK10595

PATENT

<b>NAME OF SUBMITTER:</b>	MARK POLYAKOV
<b>SIGNATURE:</b>	/Mark Polyakov/
<b>DATE SIGNED:</b>	05/02/2019
<b>Total Attachments: 16</b> source=ELKAssignment#page1.tif source=ELKAssignment#page2.tif source=ELKAssignment#page3.tif source=ELKAssignment#page4.tif source=ELKAssignment#page5.tif source=ELKAssignment#page6.tif source=ELKAssignment#page7.tif source=ELKAssignment#page8.tif source=ELKAssignment#page9.tif source=ELKAssignment#page10.tif source=ELKAssignment#page11.tif source=ELKAssignment#page12.tif source=ELKAssignment#page13.tif source=ELKAssignment#page14.tif source=ELKAssignment#page15.tif source=ELKAssignment#page16.tif	

## PATENTS ASSIGNMENT AGREEMENT

THIS PATENTS ASSIGNMENT AGREEMENT (the "Agreement") is effective as of November 26, 2018 (the "Effective Date"), by and between **NOVARTIS AG**, a company organized under the laws of Switzerland and located at Lichtstrasse 35, 4056 Basel, Switzerland ("NAG"), **VIVACTA LIMITED**, having a registered office at 200 Frimley Business Park, Frimley, Camberley, Surrey, GU16 7SR ("Vivacta") (NAG and Vivacta collectively the "Assignor"), and **PSYROS DIAGNOSTICS LIMITED** (the "Assignee"), a corporation organized under the laws of the UK with a registered office at 41b Beach Road, Littlehampton, West Sussex, England BN17 5JA United Kingdom (each referred to individually as a "Party" and together as the "Parties").

WHEREAS, the Parties have entered into an Asset Purchase Agreement as of November 26, 2018 ("APA") for the sale of certain assets and intellectual property related to the Novartis Near Patient Testing Unit;

WHEREAS, Assignor is the owner of the patents and patent applications described in Annex IV of the APA and described in more detail in Schedule A hereto ("Assigned Patents");

WHEREAS, in accordance with and subject to the APA, Assignee desires to obtain from Assignor, and Assignor wishes to assign to Assignee, all of Assignor's right, title and interest in and to the Assigned Patents;

NOW, THEREFORE, the Parties agree as follows:

### 1. ASSIGNMENT OF RIGHTS

1.1 **Assignment of Rights.** For good and valuable consideration, the sufficiency of which is hereby acknowledged, Assignor, as beneficial and legal owner, hereby assigns and transfers, and shall cause any other necessary person or entity to assign and transfer, to Assignee, its interest in the Assigned Patents, to hold the same unto and to the use of Assignee, its successors and assigns absolutely during the term for which any letters patent that shall be granted. Upon request by Assignee, without additional consideration, Assignor agrees to promptly execute documents, testify and take other acts as Assignee may deem necessary or desirable to procure, maintain, perfect, and enforce the full benefits, enjoyment, rights, title and interest of the Assigned Patents assigned hereunder, in Assignee's name and for its benefit.

1.2 **Sublicense to Assignor.** With respect to any Assigned Patents that are the subject of a patent application that is pending as of the Closing Date, Assignee acknowledges that it owns such Assigned Patent, including any invention claimed in any patent resulting from the application(s), subject to the non-exclusive license grant to Assignor under Clause 2.4 of the APA. Assignee hereby accepts the Assigned Patents subject to the license to Assignor, and Assignee grants, and affirms the grant of, a perpetual, irrevocable, non-exclusive, fully paid-up, sublicensable right and license to Assignor and its Affiliates in accordance with Clause 2.4 of the APA.

### 2. CONSIDERATION

2.1 **Upfront Fee.** In accordance with Clause 4.1 of the APA, Assignee shall make an upfront payment to Assignor of £1 (one British pound) on the Closing Date of the APA as

consideration for the Transferred Assets, including the Assigned Patents. Assignee shall make additional payments to Assignee as set forth in the APA.

### 3. MISCELLANEOUS

**3.1 Transfer As Is.** Except as provided for in Clause 8 of the APA or this Agreement, none of Assignor, its Affiliates or any of their respective directors, officers, employees, stockholders, partners, members, agents or representatives make any representations, or extend any warranties of any kind, either express or implied, written or oral, to Assignee or any of its Affiliates, including any representation or warranty as to the accuracy or completeness of any information regarding the Assigned Patents.

Assignee is acquiring the Assigned Patents on an "as is" basis; in this respect, Assignor makes no representation or warranty as to the patentability, validity, scope, strength, or jurisdictional coverage of any of the Assigned Patents, nor does Assignor make any representation or warranty that the practice of any invention covered by any of the Assigned Patents is free from any proprietary rights infringement or claim of infringement by any Third Party.

In accordance with Clause 8 of the APA, Assignee expressly acknowledges and agrees that it will not assert any claim against Assignor or any of its employees, agents, stockholders, Affiliates or any representatives or hold Assignor or any such persons liable for any inaccuracies, misstatements or omissions with respect to information furnished by Assignor, its Affiliates or representatives.

**3.2 Filing Responsibility and Liability.** Assignee shall be responsible for filing this Agreement with the relevant registries at its sole cost and expense, including all filing costs, notarization and external fees, such filing to occur within six (6) months of the Closing Date. Except as otherwise set forth in this Agreement or the APA, Assignor's sole obligation with regard to the transfer of the Assigned Patents will be to execute this Agreement and to assist with related formalities; provided, however, that Assignor shall provide further cooperation with respect to the execution of any documents necessary to evidence the transfers contemplated hereunder. The responsibility and expenses of preparing and filing such documents and any action required ancillary thereto shall be borne solely by Assignee. Assignee shall indemnify Assignor for, and hold it harmless against, any loss or damage, including fees, penalties or fines and Third Party claims, due to Assignee's failure to record any assignment of any Assigned Patents, unless such failure is related to any failure or delay of Assignor in performing necessary acts or to provide necessary information.

**3.3 Covenant Not to Sue.** In accordance with Clause 2.6 of the APA, Assignee acknowledges and agrees that it shall not directly or indirectly sue, assert any claim or counterclaim against or otherwise commence any action or proceeding anywhere in the world against Assignor or its Affiliates claiming or otherwise asserting infringement of any of the Assigned Patents.

**3.4 Liability.** The Parties acknowledge and agree that the limitations and exclusions of liability and disclaimers of warranty set forth in this Agreement and the APA form an essential basis of the bargain between the Parties.

**3.5 Governing Law.** This Agreement shall be governed by and construed under the Laws of England and Wales, without giving effect to the conflict of laws provision thereof. Any claim or dispute arising out of or relating to this Agreement that cannot be resolved amicably

between the Parties within sixty (60) days after the controversy has arisen shall be subject to the exclusive jurisdiction of a competent Court for the city of London, so long as it shall have subject matter jurisdiction over such claim or dispute. Each Party irrevocably agrees and consents to the jurisdiction of the courts set forth in this Section 3.4 and waives any objection it may have to the venue of such courts, including with respect to the convenience of the forum and jurisdiction.

**3.6 Entire Agreement.** This Agreement (together with the APA and any other Ancillary Agreements) constitutes the entire agreement of the Parties and supersedes all prior agreements and understandings, both written and oral, between the Parties with respect to the subject matter hereof.

**3.7 Amendment.** No amendment, modification or waiver of any terms or conditions hereof shall be effective unless made in writing and signed by both Parties.

**3.8 Assignment.** This Agreement shall not be assignable by Assignee without the prior written consent of Assignor. Any attempted assignment in contravention of this Section 3.7 shall be null, void and of no effect.

**3.9 Headings.** The headings used in this Agreement are for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement.

**3.10 Undefined Terms.** All capitalized terms used but not defined herein shall have the meanings ascribed to them in the APA.

**3.11 Notices.** All notices, consents, waivers, and other communications under this Agreement shall be given in accordance with Clause 11.4 of the APA.

**3.12 Counterparts; Transmission by Facsimile.** This Agreement may be executed in counterparts, with the same force and effect as if the parties had executed the same agreement. This Agreement may be executed and delivered electronically or by facsimile, and any such execution and delivery shall be legally binding for all legal purposes.

**3.13 Severability.** If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not be in any way affected or impaired thereby.

**3.14 Waiver.** Any waiver by either party of any breach of this Agreement shall not constitute a waiver of any subsequent or other breach.

**3.15 Construction.** The Parties have participated jointly in the negotiation and drafting of this Agreement. In the event that an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the Parties and no presumption or burden of proof shall arise favoring or disfavoring any Party by virtue of the authorship of any of the provisions of this Agreement. Except where the context otherwise requires, where used, the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders and the word "or" is used in the inclusive sense (and/or). The term "including" as used herein means including the generality of any description preceeding such term.

**3.16 Inconsistency or Conflict of Terms.** In the event of a conflict or inconsistency between the terms of the APA and this Agreement, the APA shall prevail.

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the Effective Date.

PSYROS DIAGNOSTICS LIMITED

By:  \_\_\_\_\_

Name: S. Ross

Title: DIRECTOR

VIVACTA LIMITED

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

NOVARTIS AG

By:  \_\_\_\_\_

Name: Nicholas Finnie  
Authorized Signatory

Title: \_\_\_\_\_

NOVARTIS AG

By:  \_\_\_\_\_

Name: Melanie K. Martin

Title: Head Legal TRD

3.16 Inconsistency or Conflict of Terms. In the event of a conflict or inconsistency between the terms of the APA and this Agreement, the APA shall prevail.

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the Effective Date.


PSYROS DIAGNOSTICS LIMITED

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

VIVACTA LIMITED

By:  \_\_\_\_\_

Name: ORIANE LACAZE

Title: CEO

NOVARTIS AG

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

NOVARTIS AG

By: \_\_\_\_\_

Name: \_\_\_\_\_

Title: \_\_\_\_\_

Schedule A

**Schedule A  
to the Patents Assignment Agreement**

**(See attached)**



**SCHEDULE A TO PATENT ASSIGNMENT**

Case references	Family Number	Country	Current Status	First Filing	Filing Number	Filing Date	Publication or Grant Number	Grant Date	Expiry Date 1 <sup>st</sup> Title	Legal Owner (List)
PAT055658	PAT055658	SI	Abandoned/Expired	United Kingdom (PSP) - 10 Apr 2003	101552702	08 Apr 2004	13 Jan 2006 07892406	24 Jun 2014	Characteristic measurement using lysine zwitterion	Novartis AG
PAT055659-UK-PC		United Kingdom	Grant	United Kingdom (PSP) - 10 Apr 2003			13 Jan 2006 07892406		Time-resolved calorimetric measurement to allow depth profiling in "dry"	Novartis AG
PAT055659-NL-RP		Netherlands	Grant	United Kingdom (PSP) - 10 Apr 2003	04726274	08 Apr 2004	13 Jan 2006 07892406	24 Jun 2014	Time-resolved calorimetric measurement to allow depth profiling in "dry"	Novartis AG
PAT055659-CA-PC		Canada	Grant	United Kingdom (PSP) - 10 Apr 2003	2821273	08 Apr 2004	13 Jan 2006 07892406	24 Jun 2014	Time-resolved calorimetric measurement to allow depth profiling in "dry"	Novartis AG
PAT055659-DE-RP		Germany	Grant	United Kingdom (PSP) - 10 Apr 2003	04726274	08 Apr 2004	13 Jan 2006 07892406	24 Jun 2014	Time-resolved calorimetric measurement to allow depth profiling in "dry"	Novartis AG
PAT055659-AT-PC		Austria	Grant	United Kingdom (PSP) - 10 Apr 2003	04726274	08 Apr 2004	13 Jan 2006 07892406	24 Jun 2014	Time-resolved calorimetric measurement to allow depth profiling in "dry"	Novartis AG
PAT055659-EP-PC		Spain	Grant	United Kingdom (PSP) - 10 Apr 2003	299650367	08 Apr 2004	13 Jan 2006 07892406	24 Jun 2014	Time-resolved calorimetric measurement to allow depth profiling in "dry"	Novartis AG
PAT055659-DE-PC		Germany	Grant	United Kingdom (PSP) - 10 Apr 2003	04726274	08 Apr 2004	13 Jan 2006 07892406	24 Jun 2014	Time-resolved calorimetric measurement to allow depth profiling in "dry"	Novartis AG



PAT035960-CH	Switzerland	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-CN	United Kingdom	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-DE	Germany	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-EP	France	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-ES	Spain	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-IT	Italy	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-JP	Japan	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-KR	South Korea	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-MX	Mexico	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-PL	Poland	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-PT	Portugal	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-RU	Russia	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-SG	Singapore	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-TW	Taiwan	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-UK	United Kingdom	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-US	United States of America	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-VN	Vietnam	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG
PAT035960-ZA	South Africa	Grant	United Kingdom (PSP) - 25 Jan 2006 05013883.9	24 Jan 2006	05 Dec 2007	071861696	31 Apr 2012	24 Jan 2026	Precedence Modifications to Prior art	Novartis AG

Patent No.	Applicant	IPC Class.	Pub. No.	Pub. Date	App. No.	App. Date	Exam. No.	Exam. Date	Remarks
PAT055662-IP-1	United Kingdom	G06F	2005-528466	24 May 2007	5236219	04 May 2013	04 May 2013	Various observations: Remarks AG of Programme for	
PAT055663	United Kingdom	G06F	2005-528466	24 May 2007	5236219	04 May 2013	04 May 2013	Remarks AG	
PAT055664	United Kingdom	G06F	2005-528466	24 May 2007	5236219	04 May 2013	04 May 2013	Remarks AG	
PAT055665-DE	Germany	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-US	United States of America	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-GB	United Kingdom	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-IT	Italy	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-JP	Japan	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-CN	China	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-IN	India	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-AU	Australia	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-CA	Canada	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-MX	Mexico	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-BR	Brazil	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-RU	Russia	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-KR	South Korea	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-SE	Sweden	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-NL	Netherlands	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-FR	France	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-ES	Spain	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-PT	Portugal	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-GR	Greece	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-CY	Cyprus	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-IL	Israel	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-TW	Taiwan	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-HK	Hong Kong	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-MO	Macao	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-SG	Singapore	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-TH	Thailand	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-VN	Vietnam	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-LU	Luxembourg	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-BE	Belgium	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-LI	Liechtenstein	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-CH	Switzerland	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-AT	Austria	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-SK	Slovakia	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-CZ	Czechia	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-SL	Slovenia	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-EU	European Union	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-EP	European Patent Office	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-PT	Portugal	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-GR	Greece	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-DE	Germany	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-FR	France	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-IT	Italy	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-ES	Spain	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-NL	Netherlands	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-BE	Belgium	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-LU	Luxembourg	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-CH	Switzerland	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-AT	Austria	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-SK	Slovakia	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-CZ	Czechia	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-SL	Slovenia	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-EU	European Union	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG
PAT055665-EP	European Patent Office	G06F	10756547.1	13 Aug 2008	18 May 2010	02703055662	28 Jun 2015	13 Aug 2008	Remarks AG

PAT05665-SE-EP	PAT05665	Sweden	Grant	United Kingdom (EP) - 31 Aug 2007	07248670.1	13 Aug 2008	19 May 2010	07248632	28 Jun 2015	13 Aug 2025	Empirical Assay: Synthetic Using Sensitivity to Drive Kinetics ("Fig 7")	Novartis AG
PAT05665-SB-EP	PAT05665	United Kingdom	Grant	United Kingdom (EP) - 31 Aug 2007	07248670.1	13 Aug 2008	19 May 2010	07248632	28 Jun 2015	13 Aug 2025	Empirical Assay: Synthetic Using Sensitivity to Drive Kinetics ("Fig 7")	Novartis AG
PAT05665-PR-EP	PAT05665	France	Grant	United Kingdom (EP) - 31 Aug 2007	07248670.1	13 Aug 2008	19 May 2010	07248632	28 Jun 2015	13 Aug 2025	Empirical Assay: Synthetic Using Sensitivity to Drive Kinetics ("Fig 7")	Novartis AG
PAT05665-IT-EP	PAT05665	Italy	Grant	United Kingdom (EP) - 31 Aug 2007	07248670.1	13 Aug 2008	19 May 2010	07248632	28 Jun 2015	13 Aug 2025	Empirical Assay: Synthetic Using Sensitivity to Drive Kinetics ("Fig 7")	Novartis AG
PAT05665-ES-EP	PAT05665	Spain	Grant	United Kingdom (EP) - 31 Aug 2007	07248670.1	13 Aug 2008	19 May 2010	07248632	28 Jun 2015	13 Aug 2025	Empirical Assay: Synthetic Using Sensitivity to Drive Kinetics ("Fig 7")	Novartis AG
PAT05665-GR-EP	PAT05665	United Kingdom	Grant	United Kingdom (EP) - 31 Aug 2007	07248670.1	13 Aug 2008	19 May 2010	07248632	28 Jun 2015	13 Aug 2025	Empirical Assay: Synthetic Using Sensitivity to Drive Kinetics ("Fig 7")	Novartis AG
PAT05665-CN-PCT	PAT05666	China	Grant	United Kingdom (PCT) - 03 Apr 2008	0727396.7	31 Mar 2009	25 Feb 2011	20095011470.6	13 Aug 2014	31 Mar 2024	Assays With Direct Assays With Direct	Novartis AG
PAT05665-DE-EP	PAT05666	Germany	Grant	United Kingdom (EP) - 03 Apr 2008	0727396.7	31 Mar 2009	25 Feb 2011	20095011470.6	13 Aug 2014	31 Mar 2024	Assays With Direct Assays With Direct	Novartis AG
PAT05665-FR-EP	PAT05666	France	Grant	United Kingdom (EP) - 03 Apr 2008	0727396.7	31 Mar 2009	25 Feb 2011	20095011470.6	13 Aug 2014	31 Mar 2024	Assays With Direct Assays With Direct	Novartis AG
PAT05665-CH-EP	PAT05666	Switzerland	Grant	United Kingdom (EP) - 03 Apr 2008	0727396.7	31 Mar 2009	25 Feb 2011	20095011470.6	13 Aug 2014	31 Mar 2024	Assays With Direct Assays With Direct	Novartis AG
PAT05665-US-PCT	PAT05666	United States of America	Grant	United Kingdom (EP) - 03 Apr 2008	12733322	31 Mar 2009	04 Jul 2011	9377723	16 Jun 2014	31 Mar 2024	Assays With Direct Assays With Direct	Novartis AG



PAT052895-CA ACT	United Kingdom (EP) - 21 May 2008	Grant	Disks	31 Mar 2008	31 Jul 2010	31 Mar 2008	31 Mar 2008	Small Masses Using Long Lead Displacement	Novartis AG
PAT052898-UR EPT	United Kingdom (EP) - 21 May 2008	Grant	United States of America	05 Mar 2009	05 May 2011	05 Mar 2009	05 Aug 2010	Small Molecules Having High Label Retention	Novartis AG
PAT052899-CH EPT	United Kingdom (EP) - 21 May 2008	Grant	Switzerland	31 Mar 2009	30 Dec 2010	30 Dec 2009	06 Jun 2010	Diagnosis Using Nucleic Acids Using Label	Novartis AG
PAT052900-IT EPT	United Kingdom (EP) - 21 May 2008	Grant	Italy	05 Mar 2009	05 Mar 2011	05 Mar 2009	18 Aug 2010	Diagnosis Using Label	Novartis AG
PAT052901-NA EPT	United Kingdom (EP) - 21 May 2008	Grant	Madagascar	21 Mar 2009	09 Mar 2011	09 Mar 2009	18 Aug 2010	Diagnosis Using Label	Novartis AG
PAT052902-FR EPT	United Kingdom (EP) - 21 May 2008	Grant	France	31 Mar 2009	05 Mar 2011	05 Mar 2009	18 Aug 2010	Diagnosis Using Label	Novartis AG
PAT052903-DE EPT	United Kingdom (EP) - 21 May 2008	Grant	Germany	31 Mar 2009	06 Mar 2011	06 Mar 2009	18 Aug 2010	Diagnosis Using Label	Novartis AG
PAT052904-AT EPT	United Kingdom (EP) - 21 May 2008	Grant	Austria	31 Mar 2009	05 Mar 2011	05 Mar 2009	18 Aug 2010	Diagnosis Using Label	Novartis AG
PAT052905-CH EPT	United Kingdom (EP) - 21 May 2008	Grant	Switzerland	31 Mar 2009	05 Mar 2011	05 Mar 2009	18 Aug 2010	Diagnosis Using Label	Novartis AG
PAT052906-US EPT	United Kingdom (EP) - 21 May 2008	Grant	United States of America	31 Mar 2009	05 Mar 2011	05 Mar 2009	18 Aug 2010	Diagnosis Using Label	Novartis AG
PAT052907-PL EPT	United Kingdom (EP) - 21 May 2008	Grant	Poland	31 Mar 2009	05 Mar 2011	05 Mar 2009	18 Aug 2010	Diagnosis Using Label	Novartis AG
PAT052908-ES EPT	United Kingdom (EP) - 21 May 2008	Grant	Spain	31 Mar 2009	05 Mar 2011	05 Mar 2009	18 Aug 2010	Diagnosis Using Label	Novartis AG
PAT052909-CA EPT	United Kingdom (EP) - 21 May 2008	Grant	Canada	31 Mar 2009	05 Mar 2011	05 Mar 2009	18 Aug 2010	Diagnosis Using Label	Novartis AG
PAT052910-CN EPT	United Kingdom (EP) - 21 May 2008	Grant	China	31 Mar 2009	05 Mar 2011	05 Mar 2009	18 Aug 2010	Diagnosis Using Label	Novartis AG
PAT052911-CA EPT	United Kingdom (EP) - 21 May 2008	Grant	Canada	31 Mar 2009	05 Mar 2011	05 Mar 2009	18 Aug 2010	Diagnosis Using Label	Novartis AG
PAT052912-IT EPT	United Kingdom (EP) - 21 May 2008	Grant	Italy	01 Jun 2010	27 Mar 2012	01 Jun 2010	01 Dec 2012	Diagnosis Using Label	Novartis AG
PAT052913-DE EPT	United Kingdom (EP) - 21 May 2008	Grant	Germany	31 Aug 2010	27 Jun 2012	31 Aug 2010	07 Sep 2012	Diagnosis Using Label	Novartis AG

PAT05871-GK-EP	PA105871	Greece	Grant	United Kingdom (IP) - 03 Sep 2009	10760386.2	01 Sep 2010	27 Jun 2012	5028331	07 May 2014	01 Sep 2010	Offici' Electrical	Minimize Noise Risk	Minimize Noise Risk
											Contacts to	Contacts to	
PAT05871-NL-EP	PA105871	Netherlands	Grant	United Kingdom (IP) - 03 Sep 2009	10760386.2	01 Sep 2010	27 Jun 2012	5028331	07 May 2014	01 Sep 2010	Offici' Electrical	Minimize Noise Risk	Minimize Noise Risk
											Contacts to	Contacts to	
PAT05871-ES-EP	PA105871	Spain	Grant	United Kingdom (IP) - 03 Sep 2009	10760386.2	01 Sep 2010	27 Jun 2012	5028331	07 May 2014	01 Sep 2010	Offici' Electrical	Minimize Noise Risk	Minimize Noise Risk
											Contacts to	Contacts to	
PAT05871-CH-EP	PA105871	Switzerland	Grant	United Kingdom (IP) - 03 Sep 2009	10760386.2	01 Sep 2010	27 Jun 2012	5028331	07 May 2014	01 Sep 2010	Offici' Electrical	Minimize Noise Risk	Minimize Noise Risk
											Contacts to	Contacts to	
PAT05871-TR-EP	PA105871	Turkey	Publication of grant	United Kingdom (IP) - 03 Sep 2009	10760386.2	01 Sep 2010	27 Jun 2012	5028331	07 May 2014	01 Sep 2010	Offici' Electrical	Minimize Noise Risk	Minimize Noise Risk
											Contacts to	Contacts to	
PAT05871-CN-EP	PA105871	China	Grant	United Kingdom (IP) - 03 Sep 2009	10760386.2	01 Sep 2010	27 Jun 2012	5028331	07 May 2014	01 Sep 2010	Offici' Electrical	Minimize Noise Risk	Minimize Noise Risk
											Contacts to	Contacts to	
PAT05871-JP-EP	PA105871	Japan	Publications of grant	United Kingdom (IP) - 03 Sep 2009	10760386.2	01 Sep 2010	27 Jun 2012	5028331	07 May 2014	01 Sep 2010	Offici' Electrical	Minimize Noise Risk	Minimize Noise Risk
											Contacts to	Contacts to	
PAT05871-DE-EP	PA105871	Germany	Grant	United Kingdom (IP) - 03 Sep 2009	10760386.2	01 Sep 2010	27 Jun 2012	5028331	07 May 2014	01 Sep 2010	Offici' Electrical	Minimize Noise Risk	Minimize Noise Risk
											Contacts to	Contacts to	
PAT05871-FR-EP	PA105871	France	Grant	United Kingdom (IP) - 03 Sep 2009	10760386.2	01 Sep 2010	27 Jun 2012	5028331	07 May 2014	01 Sep 2010	Offici' Electrical	Minimize Noise Risk	Minimize Noise Risk
											Contacts to	Contacts to	
PAT05871-IT-EP	PA105871	Italy	Grant	United Kingdom (IP) - 03 Sep 2009	10760386.2	01 Sep 2010	27 Jun 2012	5028331	07 May 2014	01 Sep 2010	Offici' Electrical	Minimize Noise Risk	Minimize Noise Risk
											Contacts to	Contacts to	
PAT05871-SE-EP	PA105871	Sweden	Grant	United Kingdom (IP) - 03 Sep 2009	10760386.2	01 Sep 2010	27 Jun 2012	5028331	07 May 2014	01 Sep 2010	Offici' Electrical	Minimize Noise Risk	Minimize Noise Risk
											Contacts to	Contacts to	
PAT05871-NO-EP	PA105871	Norway	Grant	United Kingdom (IP) - 03 Sep 2009	10760386.2	01 Sep 2010	27 Jun 2012	5028331	07 May 2014	01 Sep 2010	Offici' Electrical	Minimize Noise Risk	Minimize Noise Risk
											Contacts to	Contacts to	
PAT05871-AU-EP	PA105871	Australia	Grant	United Kingdom (IP) - 03 Sep 2009	10760386.2	01 Sep 2010	27 Jun 2012	5028331	07 May 2014	01 Sep 2010	Offici' Electrical	Minimize Noise Risk	Minimize Noise Risk
											Contacts to	Contacts to	



Patent No.	IPC Class	Inventor	Applicant	Pub No.	Pub Date	Pub Date	Pub Date	Pub Date	Pub Date	Pub Date	Pub Date	Pub Date
PAT036673-GB	G01S 5/00	Japan	United Kingdom (NP) - 06 Apr 2011	2014-1033110	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012
PAT036673-GB	G01S 5/00	Japan	United Kingdom (NP) - 06 Apr 2011	2014-1033110	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012
PAT036673-GB	G01S 5/00	Japan	United Kingdom (NP) - 06 Apr 2011	2014-1033110	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012
PAT036673-GB	G01S 5/00	Japan	United Kingdom (NP) - 06 Apr 2011	2014-1033110	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012
PAT036673-GB	G01S 5/00	Japan	United Kingdom (NP) - 06 Apr 2011	2014-1033110	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012
PAT036673-GB	G01S 5/00	Japan	United Kingdom (NP) - 06 Apr 2011	2014-1033110	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012
PAT036673-GB	G01S 5/00	Japan	United Kingdom (NP) - 06 Apr 2011	2014-1033110	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012
PAT036673-GB	G01S 5/00	Japan	United Kingdom (NP) - 06 Apr 2011	2014-1033110	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012	05 Apr 2012

